Navigation Links
BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
Date:5/16/2008

WOBURN, Mass., May 16 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage products in oncology and infectious disease, announced today that the abstract describing the interim results from its Phase II clinical trial of OncoVEX GM-CSF in advanced metastatic melanoma is now available at the American Society of Clinical Oncology (ASCO) website located at http://www.asco.org. A summary of the abstract which describes the data as of the submission date to ASCO in January 2008 is provided below.

Senior clinical investigator, Neil N. Senzer, M.D., will present up-to-date results of the abstract entitled "Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpes virus in unresectable metastatic melanoma," at the 2008 ASCO Annual Meeting in Chicago, IL on Sunday, June 1 at 9:30am EDT during the melanoma conference session.

A summary of the abstract follows:

Background: OncoVEX GM-CSF is a second generation oncolytic herpes simplex virus (HSV) which encodes GM-CSF. OncoVEX GM-CSF had previously been shown to be well tolerated in a phase I clinical trial in patients with a range of tumor types, in which anti-tumor effects were seen in both injected and un-injected tumors.

Phase II Study Design: Single-arm monotherapy in up to 50 patients with unresectable stage IIIc/IV metastatic melanoma.

End Points: The trial was designed to measure overall objective response, which is defined as a complete response, where disease is completely eliminated, or partial response, where there is a >30% reduction in disease burden. The target efficacy endpoint detailed in the Phase II protocol and agreed upon with the FDA was to achieve two objective responses or stable disease >2 months.

Interim Results: At the time of the abstract submission, 40 patients had been enrolled of whom 31 were evaluable. 81% had stage IV disease. With respect to systemi
'/>"/>

SOURCE BioVex Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... --  Auxilium Pharmaceuticals , Inc. (NASDAQ: AUXL ... that certain members of the executive management team will ... held September 8-10, 2014 in New York ... and President, is scheduled to present an overview of ... ET on Wednesday, September 10, 2014. The ...
(Date:8/27/2014)... PARK, Calif. , Aug. 27, 2014 ... the U.S. Food and Drug Administration (FDA) to initiate ... in patients with complete cervical spinal cord injury.  The ... 1 clinical study of the product, and is designed ... AST-OPC1 in patients with complete cervical spinal cord injuries, ...
(Date:8/27/2014)... LONDON , Aug. 27, 2014 ... solutions, MarketResearch.com is pleased to announce the addition ... Devices Knowledge Center. The Medical Devices ... latest market research in the healthcare industry. Users ... from industry expert, Kalorama Information, published from 1998 ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 2MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 3
... ADA,s 2009 Convention -- When Shawnae Jebbia won the Miss ... fairytale career. She appeared at events throughout the world, worked ... Shawnae,s world unexpectedly changed when she was diagnosed with hearing ... she had a difficult time understanding and accepting the sudden ...
... Oct. 29 Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... , Sales in local currency declined by 12% in ... negative currency impact. , Net earnings per diluted ... third quarter of 2008. Adjusted EPS was $1.36, a 6% ...
Cached Medicine Technology:Former Miss USA Shawnae Jebbia Shines with Siemens Pure 2Former Miss USA Shawnae Jebbia Shines with Siemens Pure 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 2Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 4Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 5Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 6Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 7Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 8Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 9Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 10Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 11Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 12Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 13
(Date:8/27/2014)... new UCLA study has shown this is definitely the case ... how to treat their prostate cancer. , UCLA researchers found ... a much more difficult time making treatment decisions, called decisional ... their care and their long-term outcomes. , The study should ... the findings to target men less likely to know a ...
(Date:8/27/2014)... Co-operative Research Centre into Microtechnologies, is coordinating ... innovative solutions based on microtechnologies to tackle ... life sciences, among others. IK4-Ikerlan, Ceit-IK4, IK4-Tekniker, ... with CIC microGUNE on this project, which ... Etortek 2013-2014 programme of the Government of ...
(Date:8/27/2014)... 10 portions a week of tomatoes have an 18 ... research suggests. , With 35,000 new cases every year ... is the second most common cancer in men worldwide. ... experts believe is linked to a Westernised diet and ... recommendations reduces risk of prostate cancer, researchers at the ...
(Date:8/27/2014)... This news release is available in German . ... need for medical agents to treat metastatic tumors. In case ... cancer that is often detected late, 95% of the patients ... amcure develops tumor therapeutic agents that might reduce this mortality ... has now received a total of EUR 5 million from ...
(Date:8/27/2014)... CA (PRWEB) August 27, 2014 Bedros Keuilian ... franchise in the world, the leading fitness boot camp ... TV’s Gym Rescue reality series. One thing he knows very ... as a subject matter expert in the fitness business. , ... YouTube, he lays out a step-by-step instructional guide on how ...
Breaking Medicine News(10 mins):Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Fighting prostate cancer with a tomato-rich diet 2Health News:Preclinical development of tumor therapeutic agent starts 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 3
... EP MedSystems,(Nasdaq: EPMD ) announces the following Webcast: What: ... 4:30 pm EST, Where: http://www.videonewswire.com/event.asp?id=43653 , How: ... web at the ... 856-753-8533, If ...
... in related literature. One extremely rare case was recently ... Journal of Gastroenterology because of its maximum diameter of ... clinical and histopathological findings, diagnostic methods and treatment by ... , The article reported one patient who presented to ...
... OCTOBER 25, 2007 Shire plc (LSE: ... biopharmaceutical company, announced that data from a 12-month ... Deficit Hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRANA ... in children aged 6 to 12 years. ...
... formation of a cancer is proven to be a ... a definite carcinogen, the role of Helicobacter pylori (H ... unclear. An article to be published on November 7 ... mechanism explaining the promotional effect of H pylori on ...
... Oct. 26 /PRNewswire-FirstCall/ - Transition Therapeutics Inc.,("Transition") (NASDAQ: ... of US$7.5,million representing the second half of the ... agreement with a subsidiary of,Elan Corporation, plc ("Elan") ... drug,candidate ELND-005/AZD-103. ELND-005/AZD-103 has completed Phase I ...
... 500 health ... plans on quality of care, service, WASHINGTON, Oct. 26 ... Assurance (NCQA) today unveiled the third,edition of America,s Best Health ... plans. Coinciding with the,November launch of "open season," when many ...
Cached Medicine News:Health News:Webcast Alert: EP MedSystems Announces EP MedSystems Third Quarter 2007 Earnings Conference Call Webcast 2Health News:The largest colonic lipoma to date 2Health News:Long-term 12-month safety data on ADHD patch DAYTRANA 2Health News:Helicobacter pylori inhibits intercellular communication of cultured gastric cells 2Health News:Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc 2Health News:U.S.News & World Report, NCQA Release Annual Rankings for 'America's Best Health Plans' 2Health News:U.S.News & World Report, NCQA Release Annual Rankings for 'America's Best Health Plans' 3
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
... The Laserex Tango ophthalmic laser system ... an SLT laser and a photodisruptor for ... is a frequency-doubled Nd:YAG producing pulsed 532 ... Nd:YAG producing 1064 nm. The appropriate laser ...
... is the unique combination laser system for ... of a button switch between SLT or ... Selecta Duet affords you the opportunity to ... the same setting with the benefits inherent ...
Extremely thin and smooth jaws, jaws open to 5.5 mm, cross action....
Medicine Products: